Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 platform study of novel treatment combinations in non-small cell lung cancer
MOH_2022-12-13_012231Phase 2Recruiting
- Sponsor
- Gilead Sciences
- Start
- Dec 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zimberelimab, domvanalimab, sacituzumab govitecan and etrumadenant in non-small cell lung cancer (NSCLC), sponsored by Gilead Sciences. Started Dec 2022; status: recruiting.
02
Drugs
zimberelimabdomvanalimabsacituzumab govitecanetrumadenant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2022-12-13_012231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-13_012231.